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VENCE L. BONHAM* 
[P]eople have argued for years—does science make progress, and then the 
law has to conform, or does the law set the system, and then science has to 
follow it?  It’s probably a mixture of both.  In the end, science . . . seeks for 
truth.  In the end law seeks for truth.  And in the end, both of us use our 
disciplines to shape our destiny and to ensure human progress, and we must 
do this together.1 
Justice Anthony Kennedy 
As scientists attempt to keep pace with the discoveries of the 
complexities of the human genome and its function, the question of how the 
legal profession keeps pace with the technological and scientific advances 
resulting from the unraveling of the human genome becomes increasingly 
relevant.  The genomic data produced in research laboratories and 
sequencing centers around the world is no longer only of value for the 
geneticists, epidemiologists, and bioinformaticians who mine the databases, 
it is also important for the public.  Of equal importance is the ability of non-
scientists to be able to make sense of this information.  As new and exciting, 
yet intricate, data comes forth, so do important questions: How does this 
emerging science intersect with the law?  How is the information 
disseminated or translated to the greater society? 
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Institute, NIH or Department of Health and Human Services.  Direct correspondence to Vence 
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Human Genome Research Institute, NIH, 31 Center Drive, Room B1B55, Bethesda, Maryland 
20892-2070. E-mail: bonhamv@mail.nih.gov.  The author is grateful for research assistance 
from Melissa Chong and the comments from Andre Pilon and Ori Lev. 
 1. Allan Sobel, The Intersection of Law and Science: Foreward, 54 DRAKE L. REV. 591, 
596 (2006) (quoting Justice Anthony Kennedy, AJS Launch of Institute of Forensic Science and 
Public Policy and National Commission on Forensic Science and Public Policy 25-26 (Nov. 
10, 2005) (transcript available at The Opperman Center at Drake University)). 
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The 21st Annual Saint Louis University Health Law Symposium, “Living in 
the Genetic Age: New Issues, New Challenges,” sought to engage both the 
students of Saint Louis University and the legal community in exploring the 
legal, social, and ethical implications of advances in genetic technology.  
Exploring the new understanding of the human genome and how it is 
influencing all facets of law and policy is an important area for legal 
scholarship.  Where the legal profession is positioned in the genomic 
revolution is a multifaceted question.  This Symposium issue presents the 
papers of four nationally recognized scholars, each discussing a different 
question of importance to the law as we have now entered the “genomic 
era.”2  Scientists are unraveling our understanding of the genome, and 
industry is developing new genetic and genomic technologies; however, 
lawyers must play a major role in framing the use of the new genetic and 
genomic information. 
GENETIC INFORMATION NONDISCRIMINATION ACT 
The Genetic Information Nondiscrimination Act of 2008 (GINA)3 is an 
example of diverse constituencies (e.g., researchers, biotech companies, 
genetic and disease advocacy groups) coming together with leaders on both 
sides of the aisle in Congress after a “13-year legislative saga”4 to draft and 
pass a genetic information nondiscrimination bill.  The late Senator Edward 
Kennedy called the legislation “the first major new civil rights bill of the [21st] 
century.”5  It is too early to determine whether legal scholars will agree that 
the legislation actually provides citizens of the United States a new civil right.  
What is certain, however, is that how the law will be interpreted will be 
decided by the courts.  Laurie Vasichek raises two important questions in her 
article, “Genetic Discrimination in the Workplace: Lessons from the Past and 
Concerns for the Future.”  First, was the legislation necessary at all?  
Second, is the legislation enough?6  Some groups, representing the business 
sector and the insurance industry, opposed GINA, saying it was “an 
 
 2. Genomics is defined as “[t]he integrated study of the functions of genes, their 
regulatory signals, and their interactions with the environment and other genes.” Vence L. 
Bonham, Esther Warshauer-Baker & Francis S. Collins, Race and Ethnicity in the Genome Era: 
The Complexity of the Constructs, 60 AM. PSYCHOLOGIST 9, 10 (2005). 
 3. Genetic Information Nondiscrimination Act of 2008 (GINA), Pub. L. No. 110-233, 
122 Stat. 881, 881-922 (2008) (to be codified in scattered sections of 26 U.S.C., 29 U.S.C., 
and 42 U.S.C.). 
 4. Kathy L. Hudson, M.K. Holohan & Francis S. Collins, Keeping Pace with the Times – 
The Genetic Information Nondiscrimination Act of 2008, 358 NEW ENG. J. MED. 2661, 2661 
(2008). 
 5. 154 CONG. REC., S3363 (daily ed. Apr. 24, 2008) (statement of Sen. Kennedy). 
 6. Laurie A. Vasichek, Genetic Discrimination in the Workplace: Lessons from the Past 
and Concerns for the Future, 3 ST. LOUIS U. J. HEALTH L. & POL’Y 13, 14 (2009). 
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unnecessary and costly burden on employers.”7  They said that such 
discrimination was not a problem.8  Other groups said that without federal 
legislation, the public feared misuse of genetic information by health 
insurers and employers, and that the passage of the bill would help reduce 
fears of discrimination and result in a greater willingness by the public to 
participate in genetic research and receive genetic services.9  The scope of 
GINA is limited, encompassing the areas of employment and health 
insurance.10  GINA does not address life insurance, disability insurance, or 
long-term care insurance.  GINA specifically excludes the military,11 where 
historically there have been examples of genetic discrimination against 
individuals who carry the sickle cell trait.12 
GINA reached a major milestone when agencies released interim final 
rules to implement the law.  The Equal Employment Opportunity 
Commission (EEOC) issued interim regulations implementing Title II of 
GINA on March 2, 2009.13  The Act became effective on November 21, 
2009.14  The interagency team comprised of the Internal Revenue Service, 
Department of Labor, and Department of Health and Human Services was 
tasked with implementing GINA Title I regulations, and issued preliminary 
rules on October 7, 2009.15 
As GINA becomes a part of our legal fabric, I believe that with time, we 
will answer Vasichek’s questions.16  As we enter a new decade, we will learn 
much about how we think about genetic information and privacy in the 
United States and across the world.  Commentators, utilizing their legal and 
scientific lenses, are already focused on what, if any, additional legislation 
and agency regulations are needed. 
 
 7. Andrew Pollack, Genetic Discrimination Bill moves ahead in Congress, N.Y. TIMES, 
Apr. 23, 2008, at C-1. 
 8. Id. 
 9. Lynn G. Dressler & Sharon F. Terry, How Will GINA Influence Participation in 
Pharmacogenomics Research and Clinical Testing?, 86 CLINICAL PHARMACOLOGY & 
THERAPEUTICS 472, 472-75 (2009).  
 10. See generally GINA, Pub. L. No. 110-233, § 1, 122 Stat. 881, 881 (2008).  Title I of 
GINA applies to Health Insurance and Title II applies to employment.  GINA § 1, 122 Stat. at 
881. 
 11. GINA § 209(a)(3), 122 Stat. at 919. 
 12. See, e.g., Air Force Academy Sued Over Sickle Cell Policy, N.Y. TIMES, Jan. 4, 1981, 
§ 1, at 20; Richard Severo, Air Academy to Drop Its Ban on Applicants with Sickle-Cell Gene, 
N.Y. TIMES, Feb. 4, 1981, at A1. 
 13. Regulations Under Genetic Information Nondiscrimination Act of 2008, 74 Fed. Reg. 
9056 (Mar. 2, 2009) (to be codified at 29 C.F.R. pt. 1635). 
 14. See GINA § 213, 122 Stat. at 920. 
 15. Interim Final Rules Prohibiting Discrimination Based on Genetic Information in Health 
Insurance Coverage and Group Health Plans, 74 Fed. Reg. 51,664, 51,664 (Oct. 7, 2009) 
(to be codified at 26 C.F.R. pt. 54, 29 C.F.R. pt. 2590, 45 C.F.R. pt. 144, 146, 148). 
 16. Vasichek, supra note 6, at 14. 
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Although safeguarding genetic information from misuse by health insurers 
and employers is a key prerequisite to more individualized approaches to 
medicine, many other critical challenges remain. First and foremost, we 
need to ensure that genetic tests are safe, reliable, and marketed in a clear 
and truthful manner. There are important gaps in the oversight of genetic 
tests, and multiple advisory groups have called for regulatory reform to 
ensure the analytic and clinical validity of genetic tests.  Clearly, our 
country’s substantial investment and innovation in genetic science ought to 
be matched by innovation in regulation. 
Finally, we need to look carefully at other areas of our society in which it 
might be tempting to use — or misuse — genetic information.17 
GINA was a legislative battle that brought diverse viewpoints to the 
question of how much privacy should we have over the genetic information 
that makes up “our” genome?  The rapid technological advances in the 
field of genomics and the dramatic reduction in the cost of genotyping are 
influencing the marketplace, including direct-to-consumer (DTC) genetic 
testing.18  These technological advances have removed the cost barriers to 
obtaining whole-genome data, thus exponentially expanding the range of 
research questions that geneticists can explore.  The increased speed and 
accuracy of genetic analysis has made genome-wide association studies 
(GWAS)—statistical associations between known genetic variants and 
quantitative traits—a powerful research technique.  This data is used by 
DTC genetic testing companies, such as deCode genetics, Inc.,19 
Navigenics, Inc.,20 and 23andMe, Inc.,21 to assist their customers by 
providing them genetic data in the context of the latest scientific findings.22  
As of December 29, 2009, 463 peer-reviewed research articles describing 
2,186 single nucleotide polymorphisms (SNPs) associated with diseases and 
traits were reported, ranging from abdominal aortic aneurysm, addiction, 
diabetes, and narcolepsy, as well as height and weight.23  As soon as a 
 
 17. Hudson et al., supra note 4, at 2663. 
 18. “Direct-to-consumer (DTC) genetic testing provides a consumer with access to his or 
her genetic information without necessarily involving a doctor in the process.”  Cynthia 
Marietta & Amy L. McGuire, Direct-to-Consumer Genetic Testing: Is It the Practice of 
Medicine?, 37 J.L. MED. & ETHICS 369, 369 (2009). 
 19. deCODE genetics, Inc., Home Page, http://www.decodeme.com (last visited Feb. 18, 
2010). 
 20. Navigenics, Inc., Home Page, http://www.navigenics.com (last visited Feb. 18, 
2010). 
 21. 23andMe, Inc.,Home Page, https://www.23andme.com (last visited Feb. 18, 2010). 
 22. See 23andMe, Inc., For Scientists: Open Letter to the Scientific Community, 
https://www.23andme.com/for/scientists (last visited Feb. 18, 2010). 
 23. National Human Genome Research Institute, Office of Population Genomics: A 
Catalog of Published Genome-Wide Association Studies, http://www.genome.gov/gwastudies 
(last visited Feb. 13, 2010). 
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paper is published demonstrating an association, companies can start 
testing for the association the next day.24  However, understanding the 
contribution of any SNP or set of SNPs to manifestation of a disease or trait 
is challenging even for scientists, so how can Internet-based companies 
communicate this information accurately to their customers? 
THE INTERNET AND PERSONAL GENOMIC INFORMATION 
The growth of the Internet both as a tool to disseminate genetic 
information and to facilitate social networks highlights interesting legal and 
ethical implications regarding the access to personal genetic information 
and privacy, as discussed by Sandra Soo-Jin Lee in her article, “Social 
Networking in the Age of Personal Genomics.”25  The new paradigm of 
DTC genetic testing and the ability to share your genetic information with 
others in your social network raises issues of privacy that extend beyond the 
individual being tested, to the biological family members of that individual. 
How does the new class of so-called “recreational genomics,” promoted by 
marketing strategies such as “spit parties,”26 intersect with clinical genetics 
and genomics? 
The debate about the benefits and risks of DTC genetic testing has 
expanded into a conversation about whether having genetic information can 
cause unique risk of harm or not. 
Information is generally considered a good thing.  Information may of 
course lead to benefit through some action based on information.  But, 
action can also lead to harm.  We know about harm not only from everyday 
experience and common sense but also from the field of clinical medicine.  
Approaches to weigh harm vs. benefit have been developed in clinical 
medicine to aid doctors, patients and policy-makers in deciding whether to 
obtain and how to use certain kinds of information. 
When personal genomics is used to improve health and prevent disease, the 
fundamental issues relating to benefit and harm of information are exactly 
the same as in the clinical medicine field of prevention. If information about 
risk or prognosis can be harmful in clinical medicine, is there a difference 
just because the health information is ‘genomic?’27 
 
 24. Bridget M. Kuehn, Risks and Benefits of Direct-to-Consumer Genetic Testing Remain 
Unclear, 300 JAMA 1503, 1503 (2008). 
 25. Sandra Soo-Jin Lee, Social Networking in the Age of Personal Genomics, 3 ST. LOUIS 
U. J. HEALTH L. & POL’Y 41 (2009). 
 26. See, e.g., Allen Salkin, When in Doubt, Spit It Out, N.Y. TIMES, Sept. 14, 2008, at ST1 
(giving an example of a “spit party” designed to collect saliva for genetic testing). 
 27. David F. Ransohoff & Muin J. Khoury, Personal Genomics: Information Can Be 
Harmful, 40 EUR. J. CLINICAL INVESTIGATION 64, 64 (2010). 
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Professional societies have responded to this new model of DTC genetic 
testing with a yellow caution light and a message of “buyers beware.”  The 
American Medical Association (AMA) stated that “genetic testing should only 
be made available under the supervision of a qualified health care 
professional, that physicians be educated about DTC genetic testing, and 
that the FTC enhance its regulation of companies’ marketing.”28  The 
American College of Medical Genetics (ACMG) stated: 
The health care professional should be responsible for both ordering and 
interpreting the genetic tests, as well as for pretest and posttest counseling of 
individuals and families regarding the medical significance of test results 
and the need, if any, for follow-up.  Due to the complexities of genetic 
testing and counseling, the self-ordering of genetic tests by patients over the 
telephone or the Internet, and their use of genetic “home testing” kits, is 
potentially harmful.  Potential harms include inappropriate test utilization, 
misinterpretation of test results, lack of necessary follow-up, and other 
adverse consequences.29 
23andMe, in an open letter to the medical community, states: 
At 23andMe our mission is to help our customers understand their own 
genetic information and how the current biomedical literature pertains to it. 
Our service combines genotyping with a set of tools and features that depict 
each customer's personal information clearly, yet without distorting or 
misrepresenting our current understanding of how genes combine with 
environment and other factors to produce human traits and diseases.  We 
also keep our service up-to-date by evaluating major genetic association 
studies as they are published in peer-reviewed journals, and incorporating 
them into our service after they have been satisfactorily confirmed. 
What we do not and will not do is provide medical advice to our customers.  
Though our service delivers personalized data, the information it provides is 
tailored to genotypes, not to individuals.  Initially, we will have no 
knowledge of our customers' vital signs, disease histories, family histories, 
environment, or any other medically relevant information . . . . 
These caveats aside, we at 23andMe believe that giving personalized 
genetic information to our customers can inspire them to take more 
responsibility for their own health and well-being.  We also think our tools 
will serve to educate the lay public about genetics.  At the very least, we 
 
 28. Katherine Groff, American Medical Association Adopts New Direct-to-Consumer 
Genetic Testing Policy Recommendations, MEDICAL NEWS TODAY, Aug. 14, 2008, available at 
http://www.medicalnewstoday.com/articles/118231.php. 
 29. American College of Medicine Genetics Board of Directors, ACMG Statement on 
Direct-to-Consumer Genetic Testing, 6 GENETICS MED. 60, 60 (2004), available at 
http://www.acmg.net/StaticContent/StaticPages/Direct_Consumer.pdf. 
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hope our product will stimulate conversation among doctors, patients and 
researchers about genes and their role in human health.30 
 Lee poses a question that the legal arena will play an important role in 
answering: What will the ‘democratization of the genome’ mean for health 
care and the future of large scale population-based genetic research?  We 
are on the precipice of a new age of personal genomics for the majority of 
Americans, but how will the law respond?  As we enter a new decade, the 
courts will grapple with various legal questions regarding access to, and 
control of, genetic information: Are DTC genetic testing companies 
engaged in the unlicensed practice of medicine?  And what are the privacy 
issues involved in the changing model of maintaining health information 
from a paper-based medical record in a physician’s office to utilization of 
health care system electronic health records and Internet-based personal 
health records (PHR)31 maintained by the individual?  The courts will be 
faced with balancing individual privacy rights with familial privacy rights.  
The courts will also struggle with the privacy rights of genetic information 
that individuals freely give to commercial entities and biomedical research 
databases, with the national security value of such information. 
RACE, GENETICS, AND THE BIOMEDICAL ENTERPRISE 
I have followed Jonathan Kahn’s work closely since he published his 
paper, “How a Drug Becomes ‘Ethnic’: Law, Commerce, and the Production 
of Racial Categories in Medicine,” in 2004 in the Yale Journal of Health 
Policy, Law and, Ethics.32  Kahn has challenged policymakers, scientists, and 
clinicians to comprehend how they frame commercial interest in the use of 
race in medicine and science.  In the article in this issue “Beyond BiDil: The 
Expanding Embrace of Race in Biomedical Research and Product 
Development” he probes the use of race in patents and product 
development.33  Kahn explores what he describes as the regulatory clash of 
race and commerce: “Market differentiation is one type of commercial 
imperative driving the use of race in biomedical research and product 
 
 30. 23andMe, Inc., For Physicians: Open Letter to the Medical Community, 
https://www.23andme.com/for/physicians/ (last visited Feb. 18, 2010). 
 31. Personal Health Record is typically an Internet platform designed to provide the 
individual patients control of their health information.  At their discretion, individuals can share 
health information with a wide range of Web applications, EMR systems, health and fitness 
devices, and with physicians and family members.  For an example of a personal health 
record, see Microsoft HealthVault, Home Page, available at http://healthvault.com/personal/ 
index.html (last visited Feb. 18, 2010). 
 32. Jonathan Kahn, How a Drug Becomes “Ethnic”: Law, Commerce, and the Production 
of Racial Categories in Medicine, 4 YALE J. HEALTH POL’Y L. & ETHICS 1 (2004). 
 33. Jonathan Kahn, Beyond BiDil: The Expanding Embrace of Race in Biomedical 
Research and Product Development, 3 ST. LOUIS U. J. HEALTH L. & POL’Y 61 (2009). 
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development.  More straightforward concerns for economy and efficiency 
may also be providing further impetus for continuing to use race in the face 
of genetic discovery.”34  My own research has focused on the role of 
genomics in understanding the construct of race and social identity, and the 
use of genetics and race in the clinical encounter. 
The first national study published about how physicians think about race 
and targeted pharmaceutical treatments was conducted with my colleagues.  
Our initial empirical research has found that physicians have a nuanced 
understanding of race-based therapies and a wariness of their use.35  Both 
black and white physicians in our qualitative study reported skepticism about 
the underlying premise of race-based therapies and uncertainty that 
physicians could use race to identify patients who would be the most likely to 
benefit from a drug.36  In general, the physicians included in the study did 
not believe that race was an adequate proxy for genetic variation in 
populations.37  Physicians’ appreciation of the challenges of applying race-
based therapies in the exam room means physicians are not likely to be 
uncritical acceptors of race-based drugs that are marketed to them.38  Many 
physicians in the study expressed dismay at what they perceived to be the 
primary aim of race-specific pharmaceutical trials, namely, to get 
physicians’ attention for marketing purposes. 
Nearly five years after the FDA approved BiDil, the first-ever drug 
targeted specifically to African Americans, we now have some data as to 
whether patients and health professionals embraced the drug.  After thirty 
months on the market, NitroMed, the parent company of BiDil, announced 
that it had suspended sales and marketing activities for BiDil, and due to 
poor sales it underwent a restructuring that has led to a significant reduction 
in its workforce.39  The question is why has BiDil done so poorly?  In the 
biomedical community, the approval of the drug touched off a debate over 
the utility of using race to determine treatment response.40  Will future 
medications targeted to a single racial or ethnic group be met with 
resistance in the medical community? What will be the legal ramifications of 
 
 34. Id. 
 35. Vence L. Bonham et al., Physicians’ Attitudes toward Race, Genetics, and Clinical 
Medicine, 11 GENETICS MED. 279, 279, 282-85 (2009). 
 36. Id. at 283-84. 
 37. Id. at 282-83. 
 38. Danielle Frank et al., Primary Care Physicians’ Attitudes Regarding Race-Based 
Therapies, 25 J. GEN. INTERNAL MED. (forthcoming 2010). 
 39. David Armstrong, NitroMed Halts Marketing of Drug, WALL ST. J., Jan. 16, 2008, at 
D8. 
 40. M. Gregg Bloche, Race-Based Therapeutics, 351 NEW ENG. J. MED. 2035, 2035-37 
(2004); Richard S. Cooper & Bruce M. Psaty, Diversity and Inclusiveness Should Remain the 
Guiding Principles for Clinical Trials, 112 CIRCULATION 3660, 3660-65 (2005). 
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race-based therapeutics? How will a decision whether or not to provide a 
patient a drug based upon race impact the standard of medical care? 
The final Symposium paper is from Maxwell Mehlman, “Will Directed 
Evolution Destroy Humanity, and If So, What Can We Do About It?”41  
Mehlman raises the issue of how new technologies are influencing our 
ability to manipulate, or enhance, our genetic germ line.  He states, “[t]he 
destruction of humanity as a result of ill-informed, overzealous, genetic 
manipulation would undeniably be a dreadful calamity.  If the threat is 
serious, it certainly must be averted if possible.”42  His paper focuses on the 
question of how this threat should be assessed, and specifically, what 
methodological framework should be employed?  For a number of years, 
the debate about genetic enhancements has been the scholarly focus of 
bioethicists.  However, as more examples come to the marketplace it will 
increasingly become a question for the law.  How will the Courts define 
enhancements? How will the Courts draw the distinction between a medical 
treatment and a genetic enhancement?  Who should prescribe 
enhancements?  What are the legal and ethical rights of a parent to make 
decisions regarding genetic enhancements for their child? 
LAW AND SCIENCE 
The Symposium title, “Living in the Genetic Age: New Issues, New 
Challenges,” raises multiple questions: What is, and what will be, the role of 
lawyers in addressing the issues and challenges of the genetic age? How, 
and indeed will, science and the law work together commonly to solve 
societal questions? 
To understand the law-science interface, it is necessary to look at the way 
law responds to the stimuli of scientific developments—indeed, to look 
generally at the way law is made and changed in our society. 
Science, like all human activity, takes place within a societal environment 
that provides incentives, deterrents, or neutrality with respect to the 
particular activity.  The institutions of government are the primary sources of 
these influences and are vehicles for expressing law.  In a developed society 
it is primarily the law that creates the societal environment in which scientific 
activity takes place.43 
Living in the genetic and genomic age clearly presents new issues and 
challenges for the law, and requires the legal profession to consider the 
intersection of law and science in new ways.  Training a new cadre of 
 
 41. Maxwell J. Mehlman, Will Directed Evolution Destroy Humanity, and If So, What Can 
We Do About It?, 3 ST. LOUIS U. J. HEALTH L. & POL’Y 93 (2009). 
 42. Id. 
 43. Harold P. Green, The Law-Science Interface in Public Policy Decisionmaking, 51 
OHIO ST. L.J. 375, 384 (1990). 
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lawyers with both an in-depth scientific and legal foundation is important for 
the future of genomics and its integration into society.  I am a proponent of 
law school courses that study law and science, and multidisciplinary courses 
that bring law students together with graduate students in the basic sciences.  
However, I do not believe that professional and graduate school courses are 
the only answer.  We need lawyers who think about science and its role in 
the practice of law, and who are capable of integrating the law into the 
development of science.  This is not a new conversation, but in the genetic 
age, the number of questions for which interdisciplinary expertise is needed 
has increased.  “The combination of law and science is, in short, a 
discipline of its own which includes but transcends the best of its constituent 
components.”44  My hope is that students entering the legal field today will 
consider the genetic age as an opportunity to bring their expertise to bear; 
to shape our future in the genetic and genomic era. 
EPILOGUE 
I end this foreword, as we enter a new decade in the genetic and 
genomic era, by highlighting a few events that have occurred since the 
Symposium on March 20, 2009.  Francis Collins, M.D., Ph.D, the leader of 
the International Human Genome Project and the National Human 
Genome Research Institute, was officially sworn in as the sixteenth director 
of the National Institutes of Health (NIH) on August 17, 2009.45  Dr. Collins 
was nominated by President Barack Obama on July 8, 2009 and was 
unanimously confirmed by the U.S. Senate on August 7, 2009.46  Dr. 
Collins brings his perspective as a physician-geneticist to this role as the 
leader of the largest biomedical enterprise in the world, with a budget of 
more than thirty billion dollars.47  He has presented a research agenda for 
NIH to the scientific community that includes the development of 
technologies in areas such as DNA sequencing, nanotechnology, 
proteomics, metabolomics, small-molecule screening, RNA interference, 
imaging, and computational biology.48 
In November of 2009, deCODE genetics declared chapter 11 
bankruptcy in the United States.49  On January 5, 2010, GenomeWeb 
 
 44. Carl N. Edwards, In Search of Legal Scholarship: Strategies for the Integration of 
Science into the Practice of Law, 8 S. CAL. INTERDISC. L.J. 1, 36 (1998). 
 45. Nat’l Inst. of Health, The NIH Director, http://www.nih.gov/about/director/index.htm 
(last visited Feb. 18, 2010). 
 46. Id. 
 47. Nat’l Inst. of Health, NIH Budget, http://www.nih.gov/about/budget.htm (last visited 
Feb. 18, 2010). 
 48. Francis S. Collins, Opportunities for Research and NIH, 327 SCIENCE 36, 36 (2010). 
 49. Nicholas Wade, A Genetics Company Fails, Its Research Too Complex, N.Y. TIMES, 
Nov. 18, 2009, at B-2. 
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announced that deCODE genetics had received notification from the 
Nasdaq Stock Market that the firm’s common stock would be suspended 
from trading as of the open of business on January 6, 2010.50 
A research team led by Sarah Tishkoff of the University of Pennsylvania 
and Carlos D. Bustamante of Cornell University published a study in the 
Proceedings of the National Academy of Sciences (PNAS) which suggests 
that care should be taken when conducting pharmacogenetic research 
within the racial population group described as “African American.”51  Their 
research findings highlight the genetic diversity that exists within individuals 
who self-identify as African American.  They state: "That some individuals 
who self-identify as African American show almost no West African ancestry 
and others show almost complete West African ancestry has implications for 
pharmacogenomics studies and assessment of disease risk."52 
In 2009 the New Yorker published an article “Brain Gain”53 reporting 
the underground growth of the use of drugs described as ‘neuroenhancers,’ 
a type of cognitive enhancement that is increasingly being used on college 
campuses. 
Unlike many hypothetical scenarios that bioethicists worry about—human 
clones, “designer babies”—cognitive enhancement is already in full swing.  
Even if today’s smart drugs aren’t as powerful as such drugs may someday 
be, there are plenty of questions that need to be asked about them. . . . 
Could enhancing one kind of thinking exact a toll on others? All these 
questions need proper scientific answers, but for now much of the discussion 
is taking place furtively, among the increasing number of Americans who 
are performing daily experiments on their own brains.54 
The article provided a glimpse of this new world of “enhancement drugs” 
used to maintain a competitive edge.  Researchers are seeking to keep pace 
with the growth of the off-label use of these drugs and are conducting 
studies to explore their medical implications.55 
The Symposium highlighted some of the issues and challenges that will 
face society in the age of genetic and genomic science.  Going forward, I 
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believe an important challenge for the legal profession is to train a cadre of 
lawyers knowledgeable of science and genomics to play an important role 
in the translation of the technological and scientific discoveries into benefits 
for society. 
 
